Hemab Therapeutics Holdings, Inc.(COAG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
COAG Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Hemab Therapeutics Holdings, Inc. (COAG), a Healthcare sector company. COAG is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Hemab Therapeutics Holdings, Inc. reports net income of $-24.1M, free cash flow of $-22.7M. Top institutional holders of COAG by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Novo A/S, FMR, based on the most recent SEC filings. COAG trades on the Nasdaq exchange and files with the SEC under CIK 2114044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COAG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hemab Therapeutics Holdings, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-24.1M
Free Cash Flow
Q2 2026
$-22.7M
ROIC
Q2 2026
-23.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $194.8M | — |
Get alerted when COAG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Hemab Therapeutics Holdings, Inc. including:
Top Institutional Holders of COAG
RA CAPITAL MANAGEMENT, L.P.
$286.8M7,808,627 shNovo Holdings A/S
$153.6M4,180,550 shFMR LLC
$135.8M3,697,837 shCapital International Investors
$132.4M3,603,876 shDeep Track Capital, LP
$132.3M3,602,093 shSiren, L.L.C.
$76.6M2,086,834 shAvoro Capital Advisors LLC
$70.7M1,925,150 shBain Capital Life Sciences Investors, LLC
$60.6M1,650,000 shJPMORGAN CHASE & CO
$42.3M1,152,420 shVANGUARD CAPITAL MANAGEMENT LLC
$28.7M780,758 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $286.8M | 7,808,627 |
| Novo Holdings A/S | $153.6M | 4,180,550 |
| FMR LLC | $135.8M | 3,697,837 |
| Capital International Investors | $132.4M | 3,603,876 |
| Deep Track Capital, LP | $132.3M | 3,602,093 |
| Siren, L.L.C. | $76.6M | 2,086,834 |
| Avoro Capital Advisors LLC | $70.7M | 1,925,150 |
| Bain Capital Life Sciences Investors, LLC | $60.6M | 1,650,000 |
| JPMORGAN CHASE & CO | $42.3M | 1,152,420 |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.7M | 780,758 |
More Healthcare Companies
View all Healthcare →Put COAG on your watchlist
Track score changes the day Hemab Therapeutics Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is COAG a good stock to buy?
13F Pro's AI-powered analysis of Hemab Therapeutics Holdings, Inc. (COAG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COAG are available on the COAG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. COAG is classified as a small company.
Which hedge funds own COAG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COAG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Hemab Therapeutics Holdings, Inc.'s investment landscape.